The high attrition rate for cancer drugs is discussed in this Review of the preclinical models available to cancer researchers and clinicians. The classic methods of drug discovery and analysis are described along with new preclinical strategies, including the genetically engineered mouse models and small-interfering RNA that have identified promising targeted drugs. Better knowledge of oncogenic signaling pathways and the mechanism of action of their inhibitors is probably the most effective way to improve the development of successful anticancer drugs.
- Alberto Ocana
- Atanasio Pandiella
- Ian F. Tannock
